Side-effect free RNA therapeutics active only in diseased cells
SRTD biotech secures seed financing
Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient RNA-based drugs that are active only in diseased cells. The round was led by High-Tech Gründerfonds (HTGF), alongside renowned business angels who have backed the technology from its inception.
SRTD biotech’s scientific team with co-founder Dr Bernd Hoffmann (third from right).
SRTD biotech
"If we can make RNA-based therapeutics effective only in diseased cells, we will be able to take the fear out of many diseases such as cancer. We are working to achieve this goal in the near future," Dr. Bernd Hoffmann, CEO of SRTD biotech
Side effects are usually the critical factor that limits the effectiveness of drugs against cancer or viral diseases. SRTD biotech is the first company to develop RNA-based therapeutics that are active only in diseased cells. This significantly increases both the efficacy of the treatment and its tolerability. The company is using the novel approach of ‘selectively expressed RNAs’, or seRNAs, as a first step in the development of a therapy for liver cancer and is exploiting the possibilities of its modular platform technology for further development in the field of cancer therapeutics and beyond.
"As a platform technology, seRNAs are not limited to oncology, but offer a wide range of possibilities in other therapeutic areas such as autoimmune diseases. We will collaborate with pharmaceutical and biotech companies to further establish seRNAs as a new therapeutic modality and position SRTD as a preferred partner in this market in the future," Dr Georg Lautscham, CFO, BD of SRTD biotech.
With the closing of the seed financing round, SRTD biotech is able to confirm the robustness of the platform and to attract further partners. The aim is to bring drug candidates for liver cancer into clinical development within the next three years and to make the platform available for other applications.
"Drug development is at a pivotal moment : genetic technologies can intervene in the disease process in a precise and highly efficient way and promise to enable therapies without side effects. We are delighted to support SRTD biotech in its efforts to become a leader in the rapidly evolving field of RNA-based therapeutics. As a seed investor, it is in our nature to support the development of early and disruptive technologies," Dr Angelika Vlachou, Partner at HTGF.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
